Macquarie Group Ltd. Has $39.33 Million Position in Haemonetics Co. (HAE)

Macquarie Group Ltd. trimmed its position in shares of Haemonetics Co. (NYSE:HAE) by 0.9% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 677,150 shares of the medical instruments supplier’s stock after selling 5,921 shares during the period. Macquarie Group Ltd. owned about 1.27% of Haemonetics worth $39,329,000 as of its most recent SEC filing.

A number of other large investors have also recently modified their holdings of the stock. Meadow Creek Investment Management LLC grew its holdings in Haemonetics by 20.7% during the 4th quarter. Meadow Creek Investment Management LLC now owns 7,336 shares of the medical instruments supplier’s stock valued at $426,000 after purchasing an additional 1,260 shares during the last quarter. Cornerstone Capital Management Holdings LLC. purchased a new stake in Haemonetics in the 4th quarter valued at about $1,701,000. Tyers Asset Management LLC boosted its position in Haemonetics by 20.7% in the 4th quarter. Tyers Asset Management LLC now owns 4,192 shares of the medical instruments supplier’s stock valued at $243,000 after buying an additional 720 shares during the period. TIAA CREF Investment Management LLC boosted its position in Haemonetics by 65.3% in the 4th quarter. TIAA CREF Investment Management LLC now owns 270,197 shares of the medical instruments supplier’s stock valued at $15,693,000 after buying an additional 106,740 shares during the period. Finally, Teachers Advisors LLC boosted its position in Haemonetics by 1.1% in the 4th quarter. Teachers Advisors LLC now owns 95,649 shares of the medical instruments supplier’s stock valued at $5,555,000 after buying an additional 1,039 shares during the period. Institutional investors own 99.85% of the company’s stock.

How to Become a New Pot Stock Millionaire

In other news, Director Mark W. Kroll sold 7,118 shares of the company’s stock in a transaction that occurred on Tuesday, January 2nd. The shares were sold at an average price of $63.00, for a total value of $448,434.00. Following the completion of the sale, the director now owns 33,881 shares of the company’s stock, valued at approximately $2,134,503. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Michelle L. Basil sold 389 shares of the company’s stock in a transaction that occurred on Tuesday, March 6th. The stock was sold at an average price of $72.23, for a total transaction of $28,097.47. The disclosure for this sale can be found here. Insiders sold a total of 7,621 shares of company stock valued at $484,766 in the last ninety days. Corporate insiders own 1.20% of the company’s stock.

Several equities research analysts have issued reports on HAE shares. Zacks Investment Research raised shares of Haemonetics from a “hold” rating to a “buy” rating and set a $70.00 price objective for the company in a research report on Tuesday, January 9th. Morgan Stanley raised shares of Haemonetics from an “equal weight” rating to an “overweight” rating and set a $51.00 price objective for the company in a research report on Tuesday, January 2nd. Jefferies Group boosted their price objective on shares of Haemonetics from $18.00 to $75.00 and gave the company a “buy” rating in a research report on Monday, January 8th. Raymond James Financial raised shares of Haemonetics from an “underperform” rating to a “market perform” rating in a research report on Tuesday, January 2nd. Finally, JMP Securities reissued an “outperform” rating and issued a $72.00 price objective on shares of Haemonetics in a research report on Wednesday, February 7th. One research analyst has rated the stock with a sell rating, two have given a hold rating and six have given a buy rating to the company. Haemonetics has a consensus rating of “Buy” and an average price target of $71.33.

Shares of HAE stock opened at $73.55 on Wednesday. Haemonetics Co. has a 52-week low of $38.43 and a 52-week high of $75.45. The firm has a market cap of $3,900.60, a P/E ratio of -216.32, a PEG ratio of 3.61 and a beta of 0.92. The company has a debt-to-equity ratio of 0.14, a current ratio of 1.82 and a quick ratio of 1.33.

Haemonetics (NYSE:HAE) last announced its quarterly earnings results on Tuesday, February 6th. The medical instruments supplier reported $0.62 earnings per share for the quarter, topping the consensus estimate of $0.44 by $0.18. Haemonetics had a negative net margin of 1.94% and a positive return on equity of 12.39%. The firm had revenue of $234.04 million during the quarter, compared to analysts’ expectations of $227.79 million. During the same quarter in the prior year, the company earned $0.43 EPS. The company’s revenue was up 2.7% compared to the same quarter last year. research analysts expect that Haemonetics Co. will post 1.86 earnings per share for the current fiscal year.

Haemonetics announced that its Board of Directors has authorized a stock repurchase program on Tuesday, February 6th that allows the company to repurchase $260.00 million in shares. This repurchase authorization allows the medical instruments supplier to buy shares of its stock through open market purchases. Shares repurchase programs are often a sign that the company’s board believes its shares are undervalued.

WARNING: This article was originally reported by Markets Daily and is the property of of Markets Daily. If you are viewing this article on another site, it was copied illegally and republished in violation of United States & international copyright and trademark laws. The legal version of this article can be read at https://www.themarketsdaily.com/2018/03/21/macquarie-group-ltd-has-39-33-million-position-in-haemonetics-co-hae.html.

About Haemonetics

Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company’s segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals.

Want to see what other hedge funds are holding HAE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Haemonetics Co. (NYSE:HAE).

Institutional Ownership by Quarter for Haemonetics (NYSE:HAE)

Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply